Mental Health Book

http://www.fpnotebook.com/

HaloperidolAka: Haldol

Advertisement

  1. Dosing: Haloperidol
    1. Dose
      1. Adult: 5-10 mg PO, IM, or IV
      2. Peds: 0.5-1 mg PO, IM or IV
      3. Adolescent: 1-5 mg PO, IM or IV
      4. Elderly: 0.5-2 mg PO, IM or IV
    2. Intervals: Scheduled and repeated dosing intervals
      1. May repeat every 30-60 minutes (max: 300 mg/24 hours)
      2. May dose regularly every 6-8 hours
        1. Typical effective dose: 5 mg PO, IV, or IM tid
  2. Dosing: Haloperidol decanoate (depot form)
    1. Haloperidol decanoate 100 mg IM every 4 weeks
    2. Cost effective (may be as low as $19 generic)
  3. Adverse effects
    1. See Extrapyramidal Side Effects (EPSE)
    2. Neuroleptic Malignant Syndrome
    3. Hypotension
    4. Dystonia
  4. Contraindications
    1. Pregnancy and Lactation
    2. Phencyclidine (PCP) overdose
    3. Anticholinergic syndromes

Haloperidol (C0018546)

Definition (MSH)A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
Definition (CSP)USP lists as an antipsychotic and as an "antidyskinetic" used in Tourette syndrome.
Definition (PDQ)A phenylbutylpiperadine derivative with antipsychotic, neuroleptic and antiemetic effects. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. The antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39474&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39474&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C537" NCI Thesaurus)
Definition (NCI)A phenylbutylpiperadine derivative with antipsychotic, neuroleptic and antiemetic effects. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. The antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity.
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
EnglishHaloperidol, HALOPERIDOL PREPARATION
Spanishhaloperidol
CreditsDerived from the NIH UMLS (Unified Medical Language System)


Haldol (C0591585)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
EnglishHaldol
CreditsDerived from the NIH UMLS (Unified Medical Language System)



Navigation Tree